Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 30,851

Document Document Title
WO/2023/099592A1
The present invention encompasses compounds of formula (V), wherein R1a, R1b, R2a, R2b, Z, R4, R5, R14, A, p, U, V and W have the meanings given in the claims and specification, their use as inhibitors of KRAS, pharmaceutical composition...  
WO/2023/098738A1
Provided are a compound of formula (I) and a preparation method therefor and a use thereof, and a fungicide. The compound can effectively prevent and treat plant oomycete diseases, and has excellent prevention and treatment effects on pl...  
WO/2023/101326A1
The present invention relates to a compound that is an autotaxin (ATX) inhibitor. More specifically, the present invention relates to a novel compound having an inhibitory effect on autotaxin activity, a pharmaceutical composition compri...  
WO/2023/099620A1
The present invention relates to compounds and derivatives of formula (I) which target KRAS and can be useful as agents for treatment and/or prevention of oncological diseases.  
WO/2023/096995A1
In one aspect, the disclosure relates to proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of LCK tyrosine kinase, i.e., the disclosed substituted N-(2-chloro-6-methylphenyl)-2-((6-(6-membered heterocycloalkyl)-2...  
WO/2023/093832A1
Disclosed are a tricyclic derivative and a preparation method therefor and an application thereof. Specifically, disclosed are a compound shown in formula (I) and an optical isomer thereof or a pharmaceutically acceptable salt thereof, a...  
WO/2023/096928A1
The present disclosure provides compounds and pharmaceutical compositions comprising the same. The compounds, pharmaceutical compositions thereof, and methods of using the same have a range of utilities as therapeutics, diagnostics, and ...  
WO/2023/094833A1
The present invention relates to compounds of Formula (I) that target PMS2, a component of DNA Mismatch Repair (MMR) wherein R2, R4, R6, A1, A2, A4, L and Q are each as defined herein. The present invention also relates to processes for ...  
WO/2023/097031A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand...  
WO/2023/096987A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand...  
WO/2023/094827A1
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein X1, R3, R4, a, b, p, q, r, L, and Ring A are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calciu...  
WO/2023/093399A1
Disclosed in the present invention are a benzothiazole-parent-based fluorescent probe for the detection of palladium ions, and a preparation method therefor and the use thereof. The structural formula of the fluorescent probe is as shown...  
WO/2023/093728A1
The present disclosure relates to a proteolysis-targeting chimera (PROTAC) molecule, further relates to a BRM selective degradation agent compound, and specifically provides a compound of formula (I) or a pharmaceutically acceptable salt...  
WO/2023/097007A1
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.  
WO/2023/095860A1
The present invention provides a medicine useful for treating and/or preventing COVID-19. Provided is a medicine characterized by combining: (A) a compound represented by formula (I) (where: Y is N; R1 represents an optionally substitute...  
WO/2023/089052A1
The invention relates to pharmaceutical compositions and methods of treating autophagy related diseases and disorders, and in particular neurological and/or CNS-related diseases. The present invention relates to compounds according to Fo...  
WO/2023/091606A1
Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, amon...  
WO/2023/090853A1
The present invention relates to a novel urea-based or carbamate-based P2X7 receptor antagonist compound. The novel urea-based or carbamate-based P2X7 receptor antagonist compound according to the present invention can effectively inhibi...  
WO/2023/088420A1
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.  
WO/2023/088385A1
The present invention relates to a compound for degrading an EGFR protein and the use thereof. Specifically, the present invention relates to a compound as represented by formula (I), and the definitions of each group and each substituen...  
WO/2023/088477A1
Disclosed in the present invention are a Bruton's tyrosine kinase degrading agent, which has a structure represented by general formula I; or a stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt and a prodrug...  
WO/2023/089074A1
The invention relates to pharmaceutical compositions and methods of treating autophagy related diseases and disorders, in particular for a systemic treatment thereof. The present invention relates to compounds according to Formula (I) or...  
WO/2023/092149A1
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds of the present disclosure...  
WO/2023/090822A1
The present invention provides a cannabichromenic acid derivative, a preparation method therefor, and a composition comprising same for improving cognitive function. A novel cannabichromenic acid derivative of the present invention has b...  
WO/2023/091565A1
The current invention relates to nuclear receptor-binding SET domain-containing 2 (NSD2)- targeted protein degradation reagents and pharmaceutical compositions thereof and their utility as anti- cancer agents.  
WO/2023/091674A1
Described herein are compounds which are inhibitors of oncogenic and wild-type SHP2 and methods of treatment using SHP2 inhibitors.  
WO/2023/091726A1
The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the pres...  
WO/2023/091438A1
The present invention relates to monobactam compounds of Formula I: The present invention also relates to pharmaceutical compositions comprising a monobactam compound of structural formula I or a pharmaceutically acceptable salt thereof....  
WO/2023/084206A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Het, X1, X2, L, R1, R2 and R3 are as defined in the specification, processes for their preparation, pha...  
WO/2023/086539A2
The disclosure is directed to compounds, and pharmaceutically acceptable salts thereof, that inhibit branched-chain amino acid aminotransferase 2 (BCAT2), pharmaceutical compositions comprising those compounds, and methods of using those...  
WO/2023/087027A1
Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.  
WO/2023/083297A1
Provided are small molecules inhibitory compounds of ubiquitin specific protease 1 (USP1) and compositions comprising the same. Further provided are methods for targeting ubiquitin specific protease 1 (USP1) and methods of treating disea...  
WO/2023/084473A1
The present invention discloses an N-substituted bicyclic heteroaromatic compound of formula (I), (I) wherein, R, R1, R2, R4, W1, W2, A and Het are as defined in the detailed description. The present invention further discloses methods f...  
WO/2023/084449A1
The disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein A and B are as described herein, as well as compositions and methods of using such compounds.  
WO/2023/082145A1
Provides compound of formula A, use in intermediates and bulk medicines thereof, and synthesis method thereof. The method avoids cumbersome separation and purification steps, reduces costs, improves reaction yield, avoids the use of POCl...  
WO/2023/086495A1
The present invention provides for compounds of Formula (I) wherein R1, has any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.  
WO/2023/085785A1
The present invention relates to an isoindolinone derivative compound having a glutarimide mother nucleus, and the application thereof and, more specifically, to an isoindolinone derivative compound having a glutarimide mother nucleus ha...  
WO/2023/086498A1
The present invention provides for compounds of Formula (I) (I); wherein R2 , X, and Z have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lun...  
WO/2023/084396A1
The present invention is directed to the preparation of key intermediates and synthesis of compounds (macrocyclic compounds) and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical c...  
WO/2023/084455A1
Pharmaceutical combinations comprising a lactivicin such as L TV-17 of formula (I) and one or more beta-lactamase inhibitors such as avibactam are disclosed. Lactivicin L TV-17 in combination with the beta lactamase inhibitor avibactam a...  
WO/2023/079294A1
The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder: whe...  
WO/2023/078271A1
Disclosed are an aromatic compound, a preparation method therefor, an intermediate thereof, a pharmaceutical composition thereof, and a use thereof, specifically relating to an aromatic compound shown in formula I, a tautomer, stereoisom...  
WO/2023/080652A1
Described herein novel compounds as androgen-receptor inhibitors for the treatment of prostate cancer and use thereof.  
WO/2023/078337A1
The disclosure provides for compounds and methods for modulating or inhibiting CDK8/19. In one aspect, described herein are compounds of Formula (A'), (A), (A-I), (A-II), (II), (II-I), (II-II), (III), (B), (IV), (V), (VI), and (VII), and...  
WO/2023/081441A1
The present disclosure relates to compounds of Formula (I): (I), wherein Ring A, R1, R2, R3, and m are described herein. The present disclosure relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts, hy...  
WO/2023/077726A1
The present invention provides an organic compound, a light extraction layer material, and an organic electronic device. The structure of the organic compound is represented as general formula (1). The organic compound can be used as the...  
WO/2023/077678A1
Disclosed in the present invention are a small molecule compound targeting an SRSF6 protein and a preparation method therefor and a use thereof. The compound is as represented by formula (I). A molecule can selectively inhibit abnormal c...  
WO/2023/076237A1
The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, o...  
WO/2023/072962A1
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as NF-κB-inducing kinase (NIK) inhibitors and, in particular, can induce the ...  
WO/2023/076626A1
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...  

Matches 451 - 500 out of 30,851